IMNM on Nasdaq

Immunome Inc.

We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies.3 From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

Compare with Tvardi Therapeutics, Inc., Whitehawk Therapeutics, Inc. or Ovid Therapeutics Inc., or pick any stock.

  • TickerIMNM on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersBothell, Washington1
  • Incorporated inDE2
  • Business address18702 N. Creek Parkway, Suite 100, Bothell, Wa 980112
  • Filer categoryNon-accelerated filer2

See how the biggest companies compare on our leaderboards

We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients. Key to that strategy is our deep expertise in the discovery, design, development, manufacturing, and ultimately commercialization of antibody-drug conjugates and other oncology therapeutics.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-3228.8%Operating margin4
-3060.0%Net margin4
-23.2%Revenue growth, 20254
-33.5%Return on equity4
-$200.6MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development100¢$177.3M

Out of $6.9M in revenue.4 The company lost money this year.

Financial statements

Revenue54$6.9M in 2025−50% since 2023
0$5.0M$10.0M$15.0M2023: $14.0M$14.0M20232024: $9.0M$9.0M2024−36%2025: $6.9M$6.9M2025−23%
Operating income678954-$224.1M in 2025+2066% since 2019
-$400.0M-$300.0M-$200.0M-$100.0M02019: -$10.3M-$10.3M20192020: -$12.3M-$12.3M2020+18%2021: -$25.2M-$25.2M2021+106%2022: -$36.9M-$36.9M2022+46%2023: -$109.5M-$109.5M2023+197%2024: -$305.8M-$305.8M2024+179%2025: -$224.1M-$224.1M2025−27%
Net income678954-$212.4M in 2025+1934% since 2019
-$300.0M-$200.0M-$100.0M02019: -$10.4M-$10.4M20192020: -$17.8M-$17.8M2020+71%2021: -$24.7M-$24.7M2021+39%2022: -$36.9M-$36.9M2022+49%2023: -$106.8M-$106.8M2023+189%2024: -$293.0M-$293.0M2024+174%2025: -$212.4M-$212.4M2025−28%

Every line of the income statement as filed: the last 2 fiscal years, latest first.4

Period ending2025-12-312024-12-31
Collaboration revenue$6.9M$9.0M
In-process research and development$10.0M$152.3M
Research and development$177.3M$129.5M
General and administrative$43.8M$33.0M
Total operating expenses$231.1M$314.8M
Loss from operations-$224.1M-$305.8M
Interest income$11.7M$12.8M
Net loss-$212.4M-$293.0M
Net loss per share, basic-$2.43-$5.00
Net loss per share, diluted-$2.43-$5.00
Weighted-average shares outstanding, basic87.4M shares58.6M shares
Weighted-average shares outstanding, diluted87.4M shares58.6M shares
Net loss-$212.4M-$293.0M
Unrealized (loss) gain on marketable securities-$57.0K$35.0K
Comprehensive loss-$212.5M-$292.9M

Compare Immunome Inc. with another company

Leadership

Who has led Immunome Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Purnanand D. Sarma2020–2023
  2. Clay B. Siegall2023–now

President

  1. Purnanand D. Sarma2020–2023
  2. Clay B. Siegall2023–now

Chief financial officer

  1. Richard F. Fitzgerald2020
  2. Diane M. Marcou2020
  3. Corleen M. Roche2021–2023
  4. Max Rosett2024–now
2025
Board members and other officers (22)

Timeline

  1. Oct 4, 2023New chief executive Clay B. Siegall becomes CEO12
  2. Oct 1, 2020New chief executive Purnanand D. Sarma becomes CEO13

Filings

337 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 65 major events, 137 insider forms, 45 large holders, 70 other. The latest 20:

  1. Oct 5, 20268-K EDGAR
  2. Sep 15, 20264 EDGAR
  3. Sep 11, 2026144 EDGAR
  4. Aug 14, 2026SCHEDULE 13G/A EDGAR
  5. Aug 14, 2026SCHEDULE 13G/A EDGAR
  6. Aug 12, 2026144 EDGAR
  7. Aug 12, 20264 EDGAR
  8. Aug 11, 2026S-8 EDGAR
  9. Aug 11, 202610-Q EDGAR
  10. Aug 11, 20268-K EDGAR
  11. Aug 10, 20264 EDGAR
  12. Aug 6, 20264 EDGAR
  13. Aug 6, 2026144 EDGAR
  14. Aug 4, 2026144 EDGAR
  15. Jul 27, 20264 EDGAR
  16. Jul 27, 20264 EDGAR
  17. Jul 27, 20264 EDGAR
  18. Jul 27, 20264 EDGAR
  19. Jul 27, 20264 EDGAR
  20. Jul 27, 20264 EDGAR

The 337 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

48 open-market trades by officers, directors and large owners since October 2021: 25 buys and 23 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 11, 2026Higgins JackChief Scientific OfficerSale13,200$25.32$334.2KForm 4
Aug 12, 2026Barchas IsaacDirectorSale11,048$27.25$301.1KForm 4
Aug 11, 2026Barchas IsaacDirectorSale62,291$26.23$1.6MForm 4
Aug 10, 2026Barchas IsaacDirectorSale10,125$26.07$264.0KForm 4
Aug 7, 2026Barchas IsaacDirectorSale15,248$26.06$397.4KForm 4
Aug 6, 2026Barchas IsaacDirectorSale20,840$26.06$543.1KForm 4
Aug 4, 2026Horn KinneyCHIEF BUSINESS OFFICERSale90,616$25.09$2.3MForm 4
Jul 7, 2026Horn KinneyCHIEF BUSINESS OFFICERSale1,092$25.00$27.3KForm 4
Jul 7, 2026Barchas IsaacDirectorSale16,906$24.20$409.1KForm 4
Jul 6, 2026Barchas IsaacDirectorSale83,094$24.11$2.0MForm 4
Jul 2, 2026Lechleider RobertChief Medical OfficerSale55,000$22.62$1.2MForm 4
Jul 2, 2026Barchas IsaacDirectorSale100,000$22.59$2.3MForm 4
Jun 30, 2026Barchas IsaacDirectorSale101,050$21.12$2.1MForm 4
Jun 25, 2026Lechleider RobertChief Medical OfficerSale55,000$19.85$1.1MForm 4
Jun 15, 2026Rosett MaxChief Financial OfficerSale60,000$18.23$1.1MForm 4
Jun 5, 2026BIENAIME JEAN JACQUESDirectorBuy10,500$19.45$204.3KForm 4
Jun 5, 2026BIENAIME JEAN JACQUESDirectorSale10,500$19.41$203.8KForm 4
May 15, 2026BIENAIME JEAN JACQUESDirectorBuy5,000$20.70$103.5KForm 4
Apr 2, 2026Rosett MaxChief Financial OfficerSale65,000$21.92$1.4MForm 4
Apr 2, 2026Higgins JackChief Scientific OfficerSale9,438$21.64$204.2KForm 4

All 48 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Fmr LLC16,987,553$360.0M0.0%+17,599
BlackRock, Inc.8,805,492$186.6M0.0%+636,818
State Street Corp5,494,625$116.4M0.0%+94,724
Wellington Management Group Llp5,210,216$110.4M0.0%+478,239
Redmile Group, LLC4,911,590$104.1M7.0%−647,295
Primecap Management Co/ca/4,581,431$97.1M0.1%−206,800
Vanguard Capital Management LLC4,551,289$96.4M0.0%+121,592
Driehaus Capital Management LLC4,346,139$92.1M0.5%+246,238
Enavate Sciences Gp, LLC3,613,799$76.6M22.2%No change
Geode Capital Management, LLC2,754,889$58.4M0.0%+194,225
Morgan Stanley2,407,942$51.0M0.0%−433,647
Silverarc Capital Management, LLC2,017,009$42.7M4.8%+166,731
Jpmorgan Chase & Co1,848,548$39.0M0.0%−929,288
Sofinnova Investments, Inc.1,720,316$36.5M1.9%+18,412
Readystate Asset Management LP1,605,820$34.0M2.2%+303,958
Goldman Sachs Group Inc1,512,489$32.0M0.0%+411,013
Vanguard Portfolio Management LLC1,348,979$28.6M0.0%+342,004
Principal Financial Group Inc1,347,358$28.6M0.0%−29,509
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1,250,275$26.5M0.0%+152,439
Woodline Partners LP1,000,398$21.2M0.1%−575,000
Northern Trust Corp968,346$20.5M0.0%+69,200
Charles Schwab Investment Management Inc886,193$18.8M0.0%+34,404
MetLife Investment Management, LLC859,076$18.2M0.1%+803,219
Vanguard Fiduciary Trust Co756,297$16.0M0.0%+39,902
Pivotal bioVenture Partners Investment Advisor LLC732,512$15.5M5.0%No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55